The Lahore High Court (LHC) has suspended the notification of the fixing the prices of life saving medicines.
The court has sought answers from the parties, including the caretaker Punjab government, at the next hearing.
The Lahore High Court (LHC) has suspended the notification of drug prices.
The court has asked the parties, including the caretaker Punjab government, the federal government and others were made parties, to respond at the next hearing.
Justice Shahid Karim heard the petition of citizen Aslam.
The petition pleaded the government issued a notification against the law in fixing the prices of the medicine, as it will increase prices of medicines.
“The government is withdrawing the section on fixing medicine prices from the Drug Act and caretaker government does not have this power. Democratic government are forming the next government so they could take this step.”
“The present notification is unconstitutional and unconstitutional. The court ordered to suspend the notification till the final decision of the petition,” the citizen pleaded.
The federal government announced on Wednesday an increase in the prices of 146 critical life-saving medicines. The decision, conveyed through a drug price hike notification, primarily targets essential medications crucial for treating conditions such as cancer, vaccines, and antibiotics.
Must Read: Govt jacks up prices of 146 life-saving medicines
Health Ministry officials have disclosed that the move follows a recommendation from the Drug Regulatory Authority, which proposed an increase in the prices of 262 medicines. However, the government has opted to implement adjustments exclusively for 146 medicines vital for saving lives.
Of the medicines listed for price increments, 116 are slated for price adjustments to be executed by pharmaceutical companies themselves.
Notably, the government will now exercise control over the prices of 464 medicines featured in the National Essential Medicines List, ensuring that critical medications remain accessible to the populace.
In a bold policy shift, the government has deregulated drug prices, granting pharmaceutical companies the autonomy to independently raise prices. This move underscores a paradigm shift in the governance of pharmaceutical pricing, potentially reshaping the dynamics of the healthcare industry.
As stakeholders digest the implications of these changes, concerns over affordability and access to life-saving medications loom large. While the government aims to strike a balance between ensuring the viability of pharmaceutical companies and safeguarding public health interests, the repercussions of these adjustments remain subject to scrutiny and debate.
